Kostas N. Botsoglou, MD, Rheumatology Center of WNY

A clinical pharmacist discusses the role of pharmacy benefit managers and payers in accessibility of adalimumab biosimilars.

Experts talk about the impact of the launch of adalimumab biosimilar on their clinical practices and pharmacy.

Specialists in rheumatology, dermatology and gastrointestinal disease discuss clinical trials that have shown safety and efficacy of adalimumab biosimilars in inflammatory diseases.

A clinical pharmacist reviews the various pharmacological aspects of the available adalimumab biosimilars.

Clinicians and a pharmacist provide an overview of the emerging adalimumab biosimilars in the recent years.

Drs Lio, Botsoglou, and Axelrad discuss the need for biosimilars in inflammatory diseases, and clinical pharmacist Dr Humphreys reviews the regulatory requirements for biosimilars to receive FDA approval.

Experts conclude their discussion emphasizing the importance of integrative care and how providers can improve outcomes for their patients with fibromyalgia (FM).

Experts highlight current challenges in their practice treating patients with fibromyalgia (FM).

Experts discuss how they personalize treatments for patients with fibromyalgia (FM) and the importance of improving sleep in their approach.

Experts discuss the limited combination therapy options for the treatment of fibromyalgia (FM) and how to inform patients of prospective outcomes.

Experts discuss their step therapy approaches for the treatment of fibromyalgia (FM).

Experts discuss the long-term safety and efficacy of agents used for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agents duloxetine and pregabalin for the treatment of fibromyalgia (FM).

Experts discuss the FDA approved agent milnacipran for the treatment of fibromyalgia (FM).

Experts offer their clinical experience discussing how they utilize off label drugs in the treatment of fibromyalgia (FM).

Experts offer their clinical experience with nonsteroidal anti-inflammatory drugs (NSAID) in the treatment of fibromyalgia (FM).

Experts discuss their therapeutic approach and key agents utilized in the treatment of fibromyalgia (FM).

Experts discuss treatment options for fibromyalgia (FM) and how they utilize integrative care with patients.

Experts discuss which providers often diagnose fibromyalgia (FM) and how the burden of care has changed in recent years.

Experts discuss common comorbidities for patients with fibromyalgia (FM).

Experts offer clinical experience on why fibromyalgia (FM) is challenging to diagnose and how they rule out other chronic pain disorders.

Experts offer their clinical advice on what factors, outside of clinical therapies, may mitigate symptoms of fibromyalgia (FM).

Experts discuss the common characteristics of fibromyalgia (FM) and related symptoms.

Experts discuss known risk factors of fibromyalgia (FM).

Experts discuss the pathophysiology of fibromyalgia (FM) and how it relates to other chronic pain diseases.

Experts offer their clinical experience on why fibromyalgia (FM) is often misunderstood by patients and practitioners.

Wendy Wright, DNP, Kostas Botsoglou, MD, Daniel Clauw, MD, and Benjamin Natelson, MD, present an overview of symptoms and characteristics of fibromyalgia (FM).

Closing out their discussion, experts highlight practical advice for caring for patients with SARDs in the current treatment landscape.

Shared insight on the importance of educating patients with SARDs on the value of COVID-19 vaccination.

W. Hayes Wilson, MD, and Kostas Botsoglou, MD, reflect on the importance of patient education and advocacy in managing SARDs.